智通财经APP获悉，Arvinas和辉瑞公司(PFE.US)今日宣布了正在进行的1b期临床试验TACTIVE-U子研究的初步数据。该试验评估蛋白降解剂vepdegestrant与CDK4/6抑制剂abemaciclib联用，治疗局部晚期或转移性雌激素受体阳性(ER+)/人表皮生长因子受体2阴性(HER2-)乳腺癌患者的效果和安全性。所有患者均接受过CDK4/6抑制剂的治疗。来自1b期子研究的16名患者的初步结果显示，abemaciclib(150 mg，每日两次)与3期临床试验推荐剂量(200 mg，每日一次)vepdegestrant联用具有可接受的安全性，患者临床获益率达到62.5%。
Vepdegestrant是一种具有口服生物利用度的在研蛋白降解剂，旨在靶向降解雌激素受体，作为单药或组合疗法的一部分，用于治疗ER+/HER2-乳腺癌患者。
组合疗法耐受性总体上与abemaciclib的已知安全性特征，以及vepdegestrant在其它临床试验中先前观察到的结果一致。最常见的任何级别治疗伴发不良事件(TEAE)为腹泻、恶心和疲劳。没有观察到剂量限制毒性，也没有4级或5级的TEAE。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.